Hikma buys rights to FDA-approved cancer treatment trametinib, a generic version of Novartis' (NVS) Mekinist, with 180 days ...

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces it has acquired the FDA-approved Abbreviated New Drug Application (ANDA) for trametinib tablets from ...

Given the large stake in the stock by institutions, Hikma Pharmaceuticals' stock price might be vulnerable to their trading decisions. A total of 12 investors have a ...

Amman – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has announced an exclusive licensing ...

UK-based drug companies AstraZeneca and GSK could be affected by Trump’s next decision, as Karl Matchett reports ...

Hikma Pharmaceuticals PLC HIK shares dropped 3.64% to £17.74 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100 Index UKX falling 2.92% to ...

Rucaparib has received regulatory approval from the European Medicines Agency (EMA) and the United States Food and Drug ...

Finlay Minerals Ltd. TSX-Venture Symbol: FYL All Issues: Yes Resumption (ET): 1:30 PM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed ...

The MDL was set to head to trial May 19 and involves Jazz along with generic drug maker Hikma Pharmaceutical, which was granted permission to launch the first Xyrem copycat in early 2023.

Jazz Pharmaceuticals said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its narcolepsy drug, Xyrem.